토글닫기
팝업닫기

Refusal of Unauthorized Collection of E-mail Addresses

We do not allow the unauthorized collection of e-mail addresses listed on our website. Persons engaging in unauthorized collection with e-mail address collection programs or other technical devices will be subject to criminal prosecution in accordance with the Act on Information & Communications Network Utilization and Information Protection.

Contact Us

form mail list
Name *
Tel * - -
E-mail * @
Subject *
Contents
File1
File2
Spam Check* 자동등록방지번호
* 왼쪽의 자동등록방지 코드를 입력하세요.

Consent to Collect and Use Personal Information

I agree to the terms and conditions.

Platform Technology

RNAi platform development

Lead compound discovery

Pulmonology / Neurology

Pharmacological research on OliX RNAi compounds for respiratory and neurological diseases

Ophthalmology

Pharmacological research on OliX RNAi compounds for ocular diseases

Animal Research

Testing efficacy of oligonucleotide therapeutics using animal models

Analytics

Develop analytical methods for therapeutic candidates to determine purity and stability in support of nonclinical and clinical studies

PK/TK

Develop bioanalytical methods to quantitate therapeutic candidates in biological matrices for pharmacokinetic and toxicokinetic (PK/TK) studies

CMC

Manage manufacturing, analytics and quality of therapeutic candidates

Toxicology

Conduct safety evaluation and toxicokinetic assessment of therapeutic candidates through nonclinical studies

Clinical

Establish clinical development plans for therapeutic candidates and conduct clinical studies

Management

Business Management

Purchasing

General Affairs

Facility Management

Contingency Planning

Planning

Budget/Performance Management

Mid to Long-term Business Goals/Strategy Planning

Accounting & Finance

Make official announcements about business contents, financial condition, business performance etc.

Stabilize Internal Accounting Control System

IT

IT Infrastructure Management

IT Helpdesk

Human Resources

HR Policy/System Establishment, Organization/Job Design

Recruitment/HR Management

Performance Management, Employee Welfare

HR Development

Legal Affairs

Prevent, respond, handle legal disputes

Provide risk management and compliance support

Develop IP strategies for core technologies

Quality Assurance(QA)

Verify pharmaceutical R&D processes and results

Ensure product to meet the established quality standards

Business Development

Develop/Maintain Client Relationships

Execute Licensing Agreements

New Business/Strategy Planning

Communications

Provide investment information in a timely manner to increase company value

Promote management activities and establish internal/external communication strategies

Create positive corporate culture through various in-house activities and employee education

  • Home
  • PR

PR

News

News

게시물 목록
No. Title Date View
50
OliX Doses First Patient in Clinical Trial for RNAi Therapeutic OLX10212 for Dry and Wet AMD new

OliX Doses First Patient in Clinical Trial for RNAi Therapeutic OLX10212 for Dry and Wet AMD new

  • 2023-03-28
  • 조회수 : 71
 2023-03-28 71
49
OliX Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alop

OliX Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alop

  • 2023-03-27
  • 조회수 : 83
 2023-03-27 83
48
OliX Publishes Preclinical Research Demonstrating OLX104C’s Potential as an Effective Treatment for

OliX Publishes Preclinical Research Demonstrating OLX104C’s Potential as an Effective Treatment for

  • 2022-11-28
  • 조회수 : 740
 2022-11-28 740
47
OliX Announces Positive Preclinical Data in NASH Non-human Primate Models

OliX Announces Positive Preclinical Data in NASH Non-human Primate Models

  • 2022-11-10
  • 조회수 : 522
 2022-11-10 522
46
OliX Receives IND Approval from FDA to Develop RNAi Therapeutic OLX10212 for AMD

OliX Receives IND Approval from FDA to Develop RNAi Therapeutic OLX10212 for AMD

  • 2022-08-08
  • 조회수 : 1125
 2022-08-08 1125
45
OliX Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212

OliX Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212

  • 2022-07-05
  • 조회수 : 1063
 2022-07-05 1063
44
OliX Subsidiary mCureX Announces mRNA Technology Collaboration with ToolGen for Rare Eye Disease

OliX Subsidiary mCureX Announces mRNA Technology Collaboration with ToolGen for Rare Eye Disease

  • 2022-07-05
  • 조회수 : 885
 2022-07-05 885
43
OliX to Conduct Business Meetings with Potential Partners at 2022 BIO International Convention

OliX to Conduct Business Meetings with Potential Partners at 2022 BIO International Convention

  • 2022-06-13
  • 조회수 : 947
 2022-06-13 947
42
OliX Announces Completion of Enrollment in Phase 2 Clinical Trial of OLX101A in Patients with Hypert

OliX Announces Completion of Enrollment in Phase 2 Clinical Trial of OLX101A in Patients with Hypert

  • 2022-06-07
  • 조회수 : 1080
 2022-06-07 1080
41
OliX Announces Completion of USD 45 Million Capital Raise for R&D and Financial Structure Improvemen

OliX Announces Completion of USD 45 Million Capital Raise for R&D and Financial Structure Improvemen

  • 2022-05-27
  • 조회수 : 1765
 2022-05-27 1765
40
OliX Identifies Effective Inhibition of Target Gene expression and Delivery of Candidate to Brain

OliX Identifies Effective Inhibition of Target Gene expression and Delivery of Candidate to Brain

  • 2022-05-27
  • 조회수 : 888
 2022-05-27 888
39
OliX Identifies Inhibition of Target Gene expression in Nonhuman Primate Models for NASH Candidate

OliX Identifies Inhibition of Target Gene expression in Nonhuman Primate Models for NASH Candidate

  • 2022-04-12
  • 조회수 : 1342
 2022-04-12 1342
38
OliX Pharmaceuticals to Participate in BIO-Europe Spring®

OliX Pharmaceuticals to Participate in BIO-Europe Spring®

  • 2022-03-24
  • 조회수 : 1229
 2022-03-24 1229
37
OliX Pharmaceuticals Presents Potential Utility of GalNAc-asiRNA Platform at OPT Congress

OliX Pharmaceuticals Presents Potential Utility of GalNAc-asiRNA Platform at OPT Congress

  • 2022-03-22
  • 조회수 : 1441
 2022-03-22 1441
36
OliX Pharmaceuticals to Present at SMi 13th Annual RNA Therapeutics Conference

OliX Pharmaceuticals to Present at SMi 13th Annual RNA Therapeutics Conference

  • 2022-03-22
  • 조회수 : 1113
 2022-03-22 1113
35
OliX Pharmaceuticals to Participate in BIO Partnering at JPM and Biotech Showcase 2022 Conferences

OliX Pharmaceuticals to Participate in BIO Partnering at JPM and Biotech Showcase 2022 Conferences

  • 2022-03-22
  • 조회수 : 943
 2022-03-22 943
34
OliX Pharmaceuticals Subsidiary mCureX Strengthens Scientific Advisory Board

OliX Pharmaceuticals Subsidiary mCureX Strengthens Scientific Advisory Board

  • 2022-03-22
  • 조회수 : 891
 2022-03-22 891
33
OliX Pharmaceuticals to Conduct One-on-One Meetings at BIO-Europe Digital 2021 Conference

OliX Pharmaceuticals to Conduct One-on-One Meetings at BIO-Europe Digital 2021 Conference

  • 2022-03-22
  • 조회수 : 891
 2022-03-22 891
32
OliX Pharmaceuticals Enters Agreement with Pharmaron

OliX Pharmaceuticals Enters Agreement with Pharmaron

  • 2022-03-22
  • 조회수 : 974
 2022-03-22 974
31
Hansoh Pharma and OliX Pharmaceuticals Enter into Licensing and Collaboration Agreement

Hansoh Pharma and OliX Pharmaceuticals Enter into Licensing and Collaboration Agreement

  • 2021-10-19
  • 조회수 : 3061
 2021-10-19 3061